Avidity Biosciences ( NASDAQ: RNA ) announced that it intends to offer and sell, subject to market and other conditions, $300.0 million of shares of its common stock in an underwritten public offering. In addition, Avidity intends to grant the underwriters a 30-day option to purchase up to an additional $45.
0 million of shares of common stock. Source: Press Release More on Avidity Biosciences Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline Avidity gains on early Phase 1/2 data for muscle disorder therapy BofA starts Avidity at buy, cites upcoming clinical data Seeking Alpha’s Quant Rating on Avidity Biosciences Historical earnings data for Avidity Biosciences.
